Envista Reports Third Quarter 2026 Results

Envista reported Q3 2026 sales of $691.5 million, up 3.2% year over year, with core sales growth of 2.7%; adjusted diluted EPS rose 25% to $0.40 and adjusted EBITDA increased 9% to $105.8 million, with margin up 80 bps to 15.3%. The company raised its 2026 adjusted diluted EPS guidance to $1.54–$1.58 from $1.50–$1.55 and narrowed core sales growth guidance to 3.75%–4.25%. GAAP net income included a noncash $428.1 million foreign-currency translation gain ($2.62 per diluted share), which did not affect adjusted earnings; Envista also repurchased 386,000 shares for approximately $10 million during the quarter.

Analysis

The key signal is not the GAAP EPS print: the noncash translation gain makes that figure unusable for earnings momentum. Adjusted results are cleaner, but the demand trajectory is less clean: Q3 core growth slowed materially from the nine-month pace, while the full-year sales range was narrowed around the same midpoint. The modest EPS-guide increase therefore leans more on execution and margin than on accelerating demand; the call’s bridge matters more than the headline.

There is a meaningful segment split. Equipment & Consumables is carrying stronger growth and adjusted margin expansion, while Specialty Products & Technologies’ adjusted operating margin slipped year over year despite positive growth. If sustained, that argues for favoring the former’s operating momentum within Envista rather than extrapolating broad-based margin gains. Tariff refunds also flatter reported gross profit; they are excluded from adjusted measures, so avoid treating the GAAP uplift as repeatable.

Near term, expect the call and market parsing of the guidance bridge to drive the reaction; the $428 million translation gain can create noisy screens, not cash earnings. Over 1–3 months, the test is whether Q4 demand can deliver the implied full-year outlook without relying on further cost actions. Over 6–18 months, sustained E&C margins would support a better-quality earnings mix, but weak specialty profitability or renewed dental-capex caution would undermine it. The contrarian risk is that investors over-credit adjusted EPS growth while underweighting the slowdown in core sales. No valuation or consensus data here supports chasing the initial move.

Key Decisions for Investors

• Do not trade the GAAP EPS headline as an earnings beat; anchor on adjusted operating performance and exclude the noncash translation gain from recurring-earnings estimates.
• Keep NVST neutral into the investor call rather than chase. Consider a measured long only if management confirms Q4 demand supports the updated sales range and Specialty Products & Technologies margins stabilize; otherwise, the narrower guidance range offers limited cushion.
• On the call, verify the Q4 sales and EBITDA bridge, organic demand versus acquisition contribution, segment pricing/cost trends, and the path to roughly 100% full-year free-cash-flow conversion. A miss on conversion or another deterioration in Specialty adjusted margin would falsify the improving-quality thesis.
• Monitor the tariff-refund treatment in reported versus adjusted results and the sustainability of Equipment & Consumables margin gains; do not extrapolate either one quarter of segment strength or a nonrecurring refund into forward earnings.